

**PuriCore Announces Pre-Close Trading Update for
Year Ended 31 December 2007**

***- 2007 earnings in line with expectations -
- Strong order book in Food Safety to drive growth in 2008 -***

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 20 February 2008 – PuriCore (LSE: PURI), the life sciences company focused on the control of infectious pathogens with its novel, safe antimicrobial technology, today provides a trading update prior to publication in late April 2008 of its preliminary results for the year ended 31 December 2007. PuriCore's solutions mimic the human body's production of its natural anti-microbial, hypochlorous acid, offering an entirely safe and non-hazardous approach to disinfection and sterilisation. The Company's products are used in a broad range of markets, including food retail and foodservice, medical device disinfection, wound therapy, and hospitality.

2007

PuriCore expects to announce sales for 2007 of approximately \$19.1 million, an increase of 20% over the year ended 31 December 2006. Earnings per share is expected to be reported in-line with consensus analyst estimates. PuriCore's US Sterilox Food Safety business, which targets leading retail supermarket chains, experienced 21% revenue growth in the full year 2007 vs. 2006, with approximately 185 Sterilox System installations last year, consistent with the Company's expectations at the time of its Interim results. In the UK Sterilox Endoscopy business, which targets hospital endoscope sterilisation units, the continued growth of recurring revenues combined with the expanded product portfolio of its new AER distribution partnerships (integrated during the year) drove 20% revenue growth in the period (11% on a constant currency basis).

2008

As announced last month, PuriCore was awarded an \$11 million order from one of the five largest food retailers in the US to install PuriCore's Sterilox Food Safety Systems throughout approximately half its store network in 2008. This order represents the second top-five US retailer to integrate the Sterilox Food Safety System. PuriCore also announces this week that its Sterilox Food Safety System received two additional major industry awards from NSF International, the world leader in standards development, product certification, education, and risk-management for public health and safety, and from the National Restaurant

Association. The combination of the robust pipeline in Food Safety together with the continued expansion of the UK Endoscopy business is expected to fuel significant organic growth in 2008.

New Developments

In a separate statement issued today, PuriCore announced that it has signed an agreement to acquire a portfolio of nine US patents from Electro-Chemical Technologies, Ltd. (ECT) in the field of electrolysed water and related processes. Additionally, PuriCore announced that it signed separate agreements to hire two ECT scientists who bring significant collective experience in the fields of water safety and technology. These agreements are expected to expand PuriCore's opportunities in commercial and industrial water treatment.

Greg Bosch, Chief Executive of PuriCore, said:

"We continue to be very focused on building market leadership in our core business segments and geographies for the control of infectious pathogens. We gained real traction in the Food Safety business during 2007 and look confidently towards the year ahead. With our current book of business combined with anticipated order flow, we anticipate significant top-line growth that will also enable us to achieve additional leverage of our operations."

Contacts:

PuriCore plc

Greg Bosch, Chief Executive Officer
Keith A. Goldan, Chief Financial Officer

+1 (484) 321 2700

Financial Dynamics

Ben Brewerton
Susan Quigley

+44 (0) 20 7831 3113

Notes to Editors:

All financials are unaudited.

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, wound therapy, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying

hypochlorous acid solutions as rinses, soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of *M. tuberculosis*, *MRSA*, *E.coli*, Norovirus, Avian Influenza, HIV, Polio Virus, *Helicobacter pylori*, and *Legionella*. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.